Zhejiang Multinpharma

Zhejiang Multinpharma is a Chinese pharmaceutical and chemical technology company specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and high-value intermediates. Established in 2017, the company provides Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) services, with a core competency in continuous flow microreaction technology for efficient chemical synthesis. Its product portfolio includes intermediates for oncology drugs such as Gefitinib and Larotinib, as well as Tianeptine Sodium, hydroxytyrosol, and various fine chemicals for the pharmaceutical and nutraceutical industries. The company operates a pilot plant in the Zhejiang Toumang Economic Development Zone and maintains R&D facilities in Hangzhou, serving a global client base across North America, Europe, and Asia.